SpringWorks Therapeutics sets wholesale acquisition cost for GOMEKLI at $206.25

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved GOMEKLI, a small molecule MEK inhibitor, for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection. With the approval, SpringWorks was granted a rare pediatric disease priority review voucher by the FDA. To support commercialization of GOMEKLI, SpringWorks has assembled a U.S. commercial field organization of 35 territory business managers plus regional business directors. For pricing, GOMEKLI dosing and cost will vary based on the body surface area of each patient, which takes into account both height and weight. SpringWorks has set a wholesale acquisition cost for GOMEKLI at $206.25 per mg. The company estimates that the average cost of treatment will be approximately $22,000 per month for pediatric patients and $30,000 per month for adult patients.